Analysis of Remote-ischemic Preconditioning Effects on Kidney Function
- Conditions
- Renal FunctionRenal Injury
- Interventions
- Procedure: remote ischemic preconditioning
- Registration Number
- NCT01925235
- Lead Sponsor
- University of Cologne
- Brief Summary
Patients with impaired renal function are at elevated risk for development of acute kidney injury (AKI). AKI is associated with increased risk for cardiovascular morbidity and mortality. Effective AKI prevention strategies are needed. Remote ischemic preconditioning (RIPC) is a novel and successful strategy to attenuate contrast medium induced AKI in patients undergoing elective coronary angiography.
The retrospective RenPro-TAVI Trial was designed to test the hypothesis whether remote ischemic preconditioning might attenuate kidney injury in patients receiving transcatheter aortic valve implantation (TAVI).
Patients with impaired renal function undergoing TAVI will be evaluated in respect whether they received remote ischemic preconditioning before the procedure or not. This study will give insight if RIPC might be beneficial in these patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 18
- age >= 18 years
- impaired renal function (baseline eGFR of <60 ml/min)
- high INTEGER risk score > 11
- high EuroSCORE (European system for cardiac operative risk evaluation)
- severe renal impairment (eGFR <15 ml/min and/or in chronic dialysis)
- recent (<=30 days) contrast media exposure
- patients enrolled in concomitant studies
- fertile women
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description RIPC remote ischemic preconditioning patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure plus ischemic preconditioning (intermittent arm ischemia through 4 cycles of 5-minute inflation and 5-minute deflation of a blood pressure cuff)
- Primary Outcome Measures
Name Time Method change in parameters determining renal function and injury 48 hours after TAVI serum creatinine, cystatin c, urinary neutrophil gelatinase-associated lipocalin (NGAL)
- Secondary Outcome Measures
Name Time Method acute kidney injury 48 hours after TAVI increase in serum creatinine ≥25% or ≥0.5 mg/dL above baseline at 48 hours after TAVI
Trial Locations
- Locations (1)
University Hospital of Cologne
🇩🇪Cologne, NRW, Germany